Archived explainer. For the current picture see today's GENB page.
GENERATE BIOMEDICINE (GENB) is down -10.45% in the latest session. Our newswire has captured 4 stories on GENB across 4 sources in the last 36 hours, with AI sentiment reading bearish (avg 42/100).
Generate Biomedicines (GENB) shares fell 10.45% to $12.08, driven by third-quarter financial results that missed analyst expectations. The company reported revenue of $4.22 million, significantly below the consensus estimate of $7.75 million.
Generate Biomedicines announced its third-quarter 2026 financial results on November 12, 2026, via an 8-K filing with the SEC. The company reported an earnings per share of $0.68, which was worse than the consensus estimate of $0.55. Revenue for the period came in at $4.22 million, falling short of the projected $7.75 million.
Alongside the financial release, the company provided a business update highlighting its lead candidate, GB-0895. This asset is currently being evaluated in two Phase 3 severe asthma studies for dosing twice a year. A single dose of GB-0895 has produced sustained pharmacological effects, according to the company’s disclosures.
The stock opened at $13.46 and hit a session high of $13.46 at 7:05 AM ET before sliding to a session low of $11.73 at 9:35 AM ET. Trading volume stood at 0.1 million shares, which is 0.1 times the three-month daily average.
The company has a market capitalization of $1.8 billion and remains unprofitable with a trailing twelve-month EPS of $3.28. Revenue has grown 55.9% over the trailing twelve months. The stock trades within a 52-week range of $11.00 to $22.67. On November 12, 2026, the stock printed two fresh 52-week lows.
Recent insider activity includes two sales by director Arnold Frances, totaling $201,000, with the most recent transaction occurring on November 4, 2026. There have been no insider buys in the last 90 days.
Investors will monitor the company’s upcoming participation in investor conferences and the continued progress of its Phase 3 asthma trials.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
On November 12, 2026, Generate Biomedicines Inc (NASDAQ: GENB) announced its third-quarter revenue of $4.22 million, falling short of analysts' consensus estima
GB-0895 is being evaluated in two Phase 3 severe asthma studies for dosing twice a year A single dose of GB-0895 produced sustained pharmacological...
Filed: 2026-11-12 AccNo: 0001193125-26-456921 Size: 563 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
More on GENB: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier GENB move explainers: 2026-11-12 · 2026-10-02 · 2026-10-01 · 2026-08-27 · 2026-08-26 · 2026-08-25